1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


Demographic and clinical characteristics of included patients (n = 174)
Demographics/Characteristics
 Age (mean) (yr)73.35 (SD, 14.33)
 Male (No.) (%)74 (42.5)
 NIHSS (mean)a14.29 (SD, 6.46)
Time from stroke to imaging in minutes (mean)166 (SD, 144.6)
Median; Q1–Q3; (min–max)115.8; 66–231; 16.8–823.8
Stroke onset (No.) (%)
 Witnessed136 (78.2)
 Wake-up38 (21.8)
Most proximal intracranial occlusion (No.) (%)
 ICA40 (23.0)
 M195 (54.6)
 M239 (22.4)
Tandem carotid occlusion (No.) (%)41 (23.6)
Smoking status (No.) (%)
 Never smoked101 (58.7)
 Active29 (16.7)
 Former23 (13.2)
 Unknown21 (12.1)
Drugs (No.) (%)
 Anticoagulants17 (9.8)
 Antiplatelets61 (35.1)
 Antihypertensive111 (63.8)
 Diabetes26 (14.9)
 Cholesterol72 (41.4)
Treatment received
 IVT only (No.) (%)34 (19.5)
 Endovascular therapy only (No.) (%)34 (19.5)
 IVT+endovascular therapy (No.) (%)71 (40.8)
 None (No.) (%)35 (20.1)
ASPECTS (No.) (%)
 6–10155 (89.1)
 0–5b19 (10.9)
Collateral status (No.) (%)
 4–581 (46.6)
 2–382 (47.1)
 0–1c11 (6.3)
  • Note:—Q indicates quartile; min, minimum; max, maximum; IVT, intravenous thrombolysis.
  • ↵a The retrospective scoring algorithm was used in 24 patients (13.8%) to assess NIHSS.
  • ↵b ASPECTS was 5 in 12 patients.
  • ↵c All had a score of 1.